Objective: To illustrate the significance of combined detection of anti cardiolipin (ACL) and anti-β2-glycoprotein 1 (β2-GP1) in the diagnosis of adverse pregnancy.
Methods: 60 postnatal women with adverse pregnancy presented to our hospital from March 2019 to March 2020 were enrolled as the experimental group, and 60 postnatal women with normal delivery in the same period were selected as the control group. The levels of ACL, β2-GP1 were measured to analyze the significance of the integrated detection in the diagnosis of adverse pregnancy.
Results: No obvious differences were observed in mean age, mean gestational week, mean height, number of cases of primigravida and multiparous women, educational background, place of residence between two groups (P > 0.05). The number of cases of positive β2-GP1-IgG and β2-GP1-IgM tests in experimental group were remarkably higher (P < 0.05). The number of β2-GP1-IgA positive cases in the two kinds of parturients was not notably different (P > 0.05). The ACL of the experimental parturients had a notably higher number of β2-GP1-positive cases (P < 0.001), and the combined positive cases of the experimental parturients had notably higher serum BPA and resistin levels (P < 0.001). The incidence of fetal growth restriction, premature delivery and placental abruption of experimental group were higher than those of control group (P < 0.05). There was no stillbirth in both groups.
Conclusions: The positive expression of ACL with β2-GP1 is the culprit of adverse pregnancy, and the combined diagnosis can greatly improve the clinical screening rate of adverse pregnancy and provide more evidence for subsequent treatment.
Keywords: ACL; adverse pregnancy diagnosis; combined monitoring; significance; β2-GP1.
AJTR Copyright © 2021.